Possible ways to correct severe forms of climacteric syndrome in women with endometriosis

2018 ◽  
pp. 96-101
Author(s):  
N.F. Zakharenko ◽  
◽  
N.V. Kovalenko ◽  
I.N. Retunska ◽  
◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Therapy Group ◽  
Elimination Rate ◽  
Reproductive Function ◽  
Clinical Effectiveness ◽  
Menopausal Hormone Therapy ◽  
Climacteric Syndrome ◽  
Menopausal Syndrome ◽  
Short Period ◽  
Transdermal Estrogen

Modern demographic changes in society are accompanied by an increase of women of the older age group in the general population. During this age period, along with the elimination of reproductive function in women, a complex of pathological symptoms often develops – climacteric syndrome (CS), which displays the maladaptation of various organs and systems that have estrogen receptors. An extremely topical problem of climacteric syndrome is for patients with endometriosis whose quantity is about 50% of the population. The objective: the determination of the effectiveness of the complex of medical therapy developed by us in women with severe forms of COP in the context of endometriosis. Materials and methods. Within 3 months we actively observed 60 women with an endometriosis in the anamnesis and manifestations of severe CS. By randomization, the women were divided into 2 groups depending on the chosen therapy: group 1 consisted of 30 women who, taking into account the above mentioned advantages, received the transdermal estrogen Estrogel, group 2 – 30 patients, whom a therapy by estrogen, phenibut and mebicar was assigned. Patients of both groups were given an intrauterine system with levonorgestrel. In order to conduct a comparative assessment of the clinical effectiveness of various treatment methods, the integral pathology index (IPI) was used in dynamics – before treatment, after 1, 2 and 3 months of therapy. The improvement degree (ID) of the disease clinical picture was also determined. Statistical analysis of the data was carried out on a personal computer using the programs SPSS 2000 (SPSSInc., USA) and Exel 2000 (MicrosoftInc., USA). Results. Our analysis found that as a result of the therapy received, a significant improvement in the scores was observed among patients of both subgroups. During the first two months, the effectiveness of combining menopausal hormone therapy with anti-stress medications in women with severe CS was almost 2 times greater than monotherapy with menopausal hormone therapy (Coefficient of Efficacy 1 = 2.68, Coefficient of Efficacy 2 = 1.62), indicating a faster elimination rate of CS’ symptoms using this combination. The overall effectiveness of the combination of phenybut with mebikar against the background of the use of Estrogel with an intrauterine system with levonorgestrel was 1.41 times higher compared to effectiveness of Estrogel and the levonorgestrel intrauterine system only use. Conclusion. Administration of anti-stress drugs Fenibut&Mebikar combination along with use of menopausal hormone therapy allows to reduce quickly the severity of CS manifestations, especially psychoemotional disorders almost to their full elimination in a relatively short period of time. The proposed scheme of treatment helps to eliminate quickly the symptoms of menopausal syndrome in women with endometriosis, improve and stabilize their psychological profile, restore working capacity, improve adaptation and quality of life. Key words: climacteric syndrome, endometriosis, anti-stress therapy, phenibut, mebicar, transdermal estrogen, Estrogel, intrauterine system with levonorgestrel.

scholarly journals Survey-based evaluation of the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome

2021 ◽  
Vol 14 (2) ◽  
pp. 225-233
Author(s):  
M. A. Chernyavskaya ◽  
I. A. Narkevich
Keyword(s):  
Hormone Therapy ◽  
Medical Information ◽  
Personal Characteristics ◽  
Cardiovascular Effects ◽  
Menopausal Hormone Therapy ◽  
Climacteric Syndrome ◽  
Menopausal Syndrome ◽  
Survey Results ◽  
Important Intermediate ◽  
The Difference

Objective: to evaluate the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome based on survey results.Material and methods. The authors analyzed 394 surveys of pharmaceutical specialists in Saint-Petersburg. The survey consisted of 13 questions, covered the personal characteristics of the participants (age, education, professional experience) and their knowledge about special medicines and food supplements to control climacteric symptoms, indications, and contraindications.Results. The results showed that pharmaceutical specialists saw the difference between combined oral contraceptives and menopausal hormone therapy, but they do not know about the protective cardiovascular effects of menopausal hormone therapy. Most specialists consider menopausal hormone therapy more effective than phytoestrogens, but they have no idea how it works. For most of them, there is hardly any difference between various classes of phytoestrogens. In their opinion, medical representatives and scientific conferences are the main providers of medical information.Conclusion. The analysis of the level of awareness of pharmaceutical specialists about the pharmacotherapy of menopausal syndrome based on the results of the survey revealed insufficient knowledge among pharmacy workers on a number of fundamental issues. Therefore, it is necessary to develop methodological recommendations on menopausal hormone therapy preparations and phytoestrogens-based drugs for pharmaceutical specialists who act as an important intermediate between a doctor and a patient.

scholarly journals The effects of menopausal hormone therapy on proinflammatory cytokines and immunoglobulins in perimenopausal patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease (COPD)

2018 ◽  
Vol 90 (10) ◽  
pp. 79-83
Author(s):  
A S Panevina ◽  
N S Smetneva ◽  
A M Vasilenko ◽  
M V Shestakova
Keyword(s):  
Blood Serum ◽  
Hormone Therapy ◽  
Proinflammatory Cytokines ◽  
Lavage Fluid ◽  
Menopausal Hormone Therapy ◽  
Chronic Obstructive ◽  
Menopausal Syndrome ◽  
Obstructive Pulmonary Disease ◽  
Tnf Α

Aim. To determine the effects of menopausal hormone therapy dosage on levels of proinflammatory cytokines and immunoglobulins in bodily fluids of patients with type 2 diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) during perimenopause. Materials and methods. The study included 119 perimenopausal females with moderate type 2 DM and stable COPD with signs of menopausal syndrome. Cytokine levels in bronchoalveolar lavage fluid and blood serum were measured with flow cytofluorometry (Вeckman Coulter FC500, USA) using a multiplex kit for human cytokines (BMS810FF) in adherence to the manufacturer’s instructions. The lower limit of quantification was 2.5-52.7 pg/mL. The following cytokines were studied: IL-1β, IL-6, IL-8, TNF-α and IF-γ. The data was analyzed with Flow CytomixProver 3.0 manufacturer-licensed software package. IgМ, IgG and IgА in the blood serum (Vektor-Best, Russia) were detected using an immunoenzymatic assay (Stat Fax 3200Analyzer, Awareness Technology, USA). Menopausal hormone therapy (MHT) with 17 beta-estradiol/dydrogesterone (standard - 2 mg, low - 1 mg, ultralow - 0.5 mg): 0.5/2.5 (estradiol 0.5 mg/dydrogesterone 2.5 mg) - ultralow-dose MHT, 1/10 (estradiol 1 mg/dydrogesterone 10 mg) - low-dose MHT; 2/10 (estradiol 2 mg/dydrogesterone 10 mg) - standard-dose MHT. Саrbohydrate metabolism was assessed in three groups. Results and discussion. While 2/10 MHT yielded the most prominent decrease in IL-1β, IL-6, IL-8, TNF-α and IF-γ levels in bronchoalveolar lavage fluid and blood serum, the effect was statistically insignificant compared to 0.5/2.5 and 1/10 MHT. Initially decreased IgM, IgG and IgA levels were elevated in all the three dosage groups with no significant differences between them. As to carbohydrate metabolism target values of glycemia were achieved in all three groups taking MHT. Conclusion. Standard-, low - and ultralow-dose MHT has positive effects on levels of proinflammatory cytokines and immunoglobulins characteristic of the association between type 2 DM, COPD and menopausal syndrome. The differences between the three dosage groups were statistically insignificant. Different dosage of MHT with dydrogesterone provide for improving impaired carbohydrate metabolism.

Opportunities for prevention and correction of genitourinary menopausal syndrome

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (2) ◽  
pp. 18-22 ◽  
Author(s):  
I S Zakharov
Keyword(s):  
Bone Mass ◽  
Hormone Therapy ◽  
Clinical Efficacy ◽  
Menopausal Hormone Therapy ◽  
Low Risk ◽  
Menopausal Syndrome ◽  
Leading Role ◽  
Number Of Publications ◽  
Condition Of Women ◽  
Positive Effect

In the manifestation and development of urogenital atrophic processes associated with the onset of menopause, the leading role is played by the growing deficiency of estrogens. An important circumstance is the fact that genitourinar menopausal disorders are often accompanied by other climacteric disorders. In this regard, a key place in the prevention and correction of hypoestrogenic conditions is systemic menopausal hormone therapy. Among the representatives of systemic menopausal hormone therapy, clinical efficacy and low risk of possible complications were demonstrated by preparations containing 17b-estradiol in combination with drospirenone. In the literature there is a significant number of publications reflecting the positive effect of these drugs on the condition of women with vasomotor, psychoemotional climacteric disorders, with a decrease in bone mass. Also, these drugs are used in the therapy and prevention of atrophic processes of the urogenital tract. This allows us to apply this combination of hormones in the complex correction of systemic and local genitourinary menopausal disorders.

scholarly journals TOFISOPAM: PROSPECTS FOR NON-HORMONAL THERAPY OF NEURO-VEGETATIVE AND PSYCHO-EMOTIONAL DISORDERS ASSOCIATED WITH MENOPAUSAL SYNDROME

2017 ◽  
pp. 88-91 ◽  
Author(s):  
Y. E. Dobrokhotova ◽  
L. V. Saprykina
Keyword(s):  
Hormone Therapy ◽  
Emotional Disorders ◽  
Hormonal Therapy ◽  
Hormonal Treatment ◽  
Climacteric Syndrome ◽  
Efficacy And Safety ◽  
Review Of Literature ◽  
Menopausal Syndrome ◽  
Number Of Factors ◽  
Perimenopausal Women

Despite the proven effect of menopausal hormone therapy on menopausal syndrome, a number of factors prevent perimenopausal women from receiving the treatment. The article is a review of literature on the possibility of non-hormonal treatment with tofisopam for neuro-vegetative and psycho-emotional disorders associated with climacteric syndrome. The article tells about the efficacy and safety of the drug taking into account its pharmacodynamic properties.

scholarly journals Efficiency of Menopausal Hormone Therapy in Women with Menopausal Syndrome

Doctor Ru ◽  
2020 ◽  
Vol 19 (1) ◽  
pp. 38-41
Author(s):  
E.A. Vinokurova ◽  
◽  
I.E. Gorodnicheva ◽  
M.A. Kiseleva ◽  
◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Menopausal Syndrome

Management of patients with uterine bleeding during menopausal hormone therapy

2021 ◽  
Author(s):  
А.З. Хашукоева ◽  
М.В. Бурденко ◽  
А.В. Оверко ◽  
Т.Е. Рыжова ◽  
М.С. Сафонина
Keyword(s):  
Life Expectancy ◽  
Hormone Therapy ◽  
Uterine Bleeding ◽  
Menopausal Hormone Therapy ◽  
Menopausal Transition ◽  
Therapeutic Effects ◽  
Climacteric Syndrome ◽  
Climacteric Symptoms ◽  
Long Life ◽  
Selection Of

Тенденции по увеличению продолжительности жизни, которые наблюдаются в последние десятилетия, напрямую затрагивают деятельность акушера-гинеколога ввиду того, что женщинам необходимо не только прожить долгую жизнь, но и снизить количество заболеваний, развитие которых нередко связано с наступлением периода менопаузального перехода и постменопаузы. Задача врачей – помочь пациенткам максимально мягко войти в период постменопаузы, минимизировав проявления климактерического синдрома. В настоящее время наиболее эффективным методом терапии ранних климактерических симптомов является менопаузальная гормональная терапия. В статье рассмотрены современные подходы к проведению менопаузальной гормональной терапии при возникновении менопаузальных расстройств, подходы к подбору менопаузальной гормональной терапии с учетом особенностей каждой конкретной пациентки. Рассматриваются терапевтические эффекты и возможности менопаузальной гормональной терапии, проблемы ее приемлемости, а также ведение пациенток в постменопаузальном периоде с маточными кровотечениями. The trends in life expectancy that have been observed in recent decades directly affect the activities of an obstetrician-gynecologist due to the fact that women need not only to live a long life, but also to reduce the number of diseases, the development of which is often associated with the onset of the menopausal transition and postmenopause. The task of doctors is to help patients to enter the postmenopausal period as gently as possible, minimizing the manifestations of the climacteric syndrome. Currently, the most effective method of treating early climacteric symptoms is menopausal hormone therapy. The article discusses modern approaches to the conduct of menopausal hormone therapy in the event of menopausal disorders, approaches to the selection of menopausal hormone therapy, taking into account the characteristics of each individual patient. The therapeutic effects and possibilities of menopausal hormone therapy, the problems of its acceptability, as well as the management of postmenopausal patients with uterine bleeding are considered.

scholarly journals Phytoestrogens in treatment of climacteric syndrome as an alternative to menopausal hormone therapy

2020 ◽  
Author(s):  
M. I. Mazitova ◽  
I. R. Talipova ◽  
R. R. Mardieva
Keyword(s):  
Hormone Therapy ◽  
Cardiovascular System ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
International Literature ◽  
Climacteric Syndrome ◽  
Sexual Symptoms ◽  
Age Related ◽  
Plant Compounds ◽  
Age Related Changes

Russian and international literature over the last 5 years was observed to study the use of phytoestrogens in treatment of climacteric syndrome. Effects of isoflavones as the main group of phytoestrogens on vasomotor, cognitive, psychological, urogenital and sexual symptoms as well as their action on the cardiovascular system, bones, and metabolic age-related changes are considered. Phytoestrogens administration is concluded to be perspective as an alternative to menopausal hormone therapy. It is reasonable to conduct further extensive researches to evaluate the effectiveness and safety of the use of the plant compounds in postmenopausal women.

Possibilities of correction of menopausal disorders in women with the use of medicine Menopace

2016 ◽  
pp. 95-100
Author(s):  
G.I. Reznichenko ◽  
◽  
N.Yu. Reznichenko ◽  
V.Yu. Potebnya ◽  
K.I. Kovalenko ◽  
...  
Keyword(s):  
General Condition ◽  
Clinical Symptoms ◽  
Average Score ◽  
Control Group ◽  
Climacteric Syndrome ◽  
Basic Subgroup ◽  
Menopausal Syndrome ◽  
Natural Menopause ◽  
Surgical Menopause ◽  
Observation Period

The objective: to determine the efficacy of medicine «Menopace» in treatment of women with natural and surgical menopause. Patients and methods. 20 women (I group) with a natural menopause were examined (basic subgroup consisted of 10 patients who used Menopace for 3 months; control subgroup consisted of 10 patients). 20 women (II group) with surgical menopause were examined (basic subgroup consisted of 10 patients who received Menopace for 3 months; control subgroup consisted of 10 patients). Results. The average score of neurovegetative and emotional manifestations of climacteric syndrome during the observation period decreased in women with natural and surgical menopause who used Menopace, compared with subgroups of patients who had not used the medicine. Conclusions. 1. The use of the medicine Menopace in women with natural menopause after 3 months showed the disappearance of clinical symptoms of climacteric syndrome in 70% of the cases, and significant improvement in general condition in 30% of cases. 2. During surgical menopause after 1 month of treatment with Menopace manifestations of sweating were observed 4.5 times less often than in control group, tides were observed 7 times less often than in control group. Neurovegetative and psychoemotional symptoms of menopause were absent in 80% of women after 3 months of treatment and in 20% of cases significant improvement was shown. 3. The obtained results give grounds to recommend wide use of Menopace in practical work for the treatment of menopausal syndrome during natural and surgical menopause. Key words: menopause, therapy, Menopace.

Menopausal hormone therapy and uterine cancer: the acceptability of the tandem

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (6) ◽  
pp. 42-47
Author(s):  
O V Yakushevskaya ◽  
S V Yureneva ◽  
A E Protasova ◽  
G N Khabas ◽  
M R Dumanovskaya
Keyword(s):  
Hormone Therapy ◽  
Uterine Cancer ◽  
Menopausal Hormone Therapy ◽  
Medical Rehabilitation ◽  
Cytostatic Treatment ◽  
Systematic Analysis ◽  
Strict Adherence ◽  
Patient Profile ◽  
The Past

The aim of the work is to conduct a systematic analysis of the available research results on the possibility of using menopausal hormone therapy (MHT) in patients who successfully completed the treatment of endometrial cancer (EC). Materials and methods. The review includes data from foreign articles published in PubMed and Medline, and domestic works published on elibrary.ru over the past 40 years. Results. The results obtained allow us to consider MHT as an independent method of medical rehabilitation for women who have undergone EC. A clear patient profile should be established, allowing the use of this method, with strict adherence to health monitoring. Conclusion Patients who have successfully completed the treatment of EC require the creation of special rehabilitation conditions in the interests of maintaining health and quality of life and should be under the close attention of the doctor. Argumented approaches to the appointment of MHT in such patients will avoid complications associated with estrogen deficiency after surgery, radiation with or without systemic (cytostatic) treatment methods.

Sign in / Sign up

Export Citation Format

Share Document